Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee Sells 9,038 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 9,038 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $127,345.42. Following the transaction, the chief executive officer now owns 495,026 shares in the company, valued at $6,974,916.34. This represents a 1.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bicycle Therapeutics Price Performance

BCYC opened at $14.88 on Tuesday. The business has a 50 day simple moving average of $19.27 and a 200-day simple moving average of $21.86. The stock has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.26) EPS. Research analysts anticipate that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BCYC. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. B. Riley lowered their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Stephens assumed coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.25.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BCYC. Point72 Asset Management L.P. raised its holdings in Bicycle Therapeutics by 1,438.1% during the third quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after purchasing an additional 841,299 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth $14,168,000. Perceptive Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth $11,577,000. Principal Financial Group Inc. acquired a new position in Bicycle Therapeutics during the third quarter worth $10,028,000. Finally, Westfield Capital Management Co. LP raised its holdings in Bicycle Therapeutics by 21.5% during the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after purchasing an additional 327,089 shares during the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.